These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 28759124)
21. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. Brouwer NJ; Verdijk RM; Heegaard S; Marinkovic M; Esmaeli B; Jager MJ Prog Retin Eye Res; 2022 Jan; 86():100971. PubMed ID: 34015548 [TBL] [Abstract][Full Text] [Related]
22. Pathology and genetics of uveal melanoma. Griewank KG; Murali R Pathology; 2013 Jan; 45(1):18-27. PubMed ID: 23222249 [TBL] [Abstract][Full Text] [Related]
23. Ocular melanoma: an overview of the current status. Jovanovic P; Mihajlovic M; Djordjevic-Jocic J; Vlajkovic S; Cekic S; Stefanovic V Int J Clin Exp Pathol; 2013; 6(7):1230-44. PubMed ID: 23826405 [TBL] [Abstract][Full Text] [Related]
26. Outcome Measures of New Technologies in Uveal Melanoma: Review from the European Vision Institute Special Interest Focus Group Meeting. Beenakker JM; Brouwer NJ; Chau C; Coupland SE; Fiorentzis M; Heimann H; Heufelder J; Joussen AM; Kiilgaard JF; Kivelä TT; Piperno-Neumann S; Rantala ES; Romanowska-Dixon B; Shields CL; Willerding GD; Wheeler-Schilling T; Scholl HPN; Jager MJ; Damato BE; Ophthalmic Res; 2023; 66(1):14-26. PubMed ID: 35358966 [TBL] [Abstract][Full Text] [Related]
27. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366 [TBL] [Abstract][Full Text] [Related]
28. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Shildkrot Y; Wilson MW Curr Opin Ophthalmol; 2009 Nov; 20(6):504-10. PubMed ID: 19644367 [TBL] [Abstract][Full Text] [Related]
29. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects. Baggetto LG; Gambrelle J; Dayan G; Labialle S; Barakat S; Michaud M; Grange JD; Gayet L Cancer Treat Rev; 2005 Aug; 31(5):361-79. PubMed ID: 15994016 [TBL] [Abstract][Full Text] [Related]
30. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort. Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710 [TBL] [Abstract][Full Text] [Related]
31. [The pathological basis of the argument in the treatment of melanoma of the uveal tract]. Li YP Zhonghua Yan Ke Za Zhi; 2012 Nov; 48(11):971-5. PubMed ID: 23302268 [TBL] [Abstract][Full Text] [Related]
37. The biology and management of uveal melanoma. Sato T; Han F; Yamamoto A Curr Oncol Rep; 2008 Sep; 10(5):431-8. PubMed ID: 18706273 [TBL] [Abstract][Full Text] [Related]
38. Liver metastasis in uveal melanoma - treatment options and clinical outcome. Kaštelan S; Mrazovac Zimak D; Ivanković M; Marković I; Gverović Antunica A Front Biosci (Landmark Ed); 2022 Feb; 27(2):72. PubMed ID: 35227015 [TBL] [Abstract][Full Text] [Related]
39. Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence? Zhao CX; Zeng CM; Wang K; He QJ; Yang B; Zhou FF; Zhu H Acta Pharmacol Sin; 2021 Feb; 42(2):179-188. PubMed ID: 32601365 [TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives. Kaštelan S; Antunica AG; Oresković LB; Pelčić G; Kasun E; Hat K Curr Med Chem; 2020; 27(8):1350-1366. PubMed ID: 31272342 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]